TriangleDISEASE & TREATMENT SETTING
Tivdak: metastatic cervical cancer after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Broader topic: Cervical Cancer
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- after chemotherapy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Tivdak (tisotumab vedotin-tftv) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
- source wording
- Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Study evidence for this setting
Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cance
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
A Trial of Tisotumab Vedotin in Cervical Cancer
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated C
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Milademetan in Advanced/Metastatic Solid Tumors
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice